Helius Medical Technologies, Inc. (HSDT)
Automate Your Wheel Strategy on HSDT
With Tiblio's Option Bot, you can configure your own wheel strategy including HSDT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HSDT
- Rev/Share 0.8615
- Book/Share 2.5409
- PB 0.1279
- Debt/Equity 0.0
- CurrentRatio 1.69
- ROIC -9.7893
- MktCap 171620.0
- FreeCF/Share -22.9796
- PFCF -0.0148
- PE -0.0125
- Debt/Assets 0.0
- DivYield 0
- ROE -4.1882
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering
Published: June 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of its public offering of an aggregate of 2,768,600 shares of its Class A common stock (or common stock equivalents), and warrants to purchase up to 2,768,600 shares of common stock, at a combined public offering price of $3.27 per share and accompanying warrants.
Read More
Helius Medical Technologies, Inc. Announces Reimbursement by Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
United Healthcare approves claim for PoNS Device at out-of-network adjusted list price, becoming the second payer to join Anthem in providing PoNS reimbursement United Healthcare approves claim for PoNS Device at out-of-network adjusted list price, becoming the second payer to join Anthem in providing PoNS reimbursement
Read More
Helius Medical Technologies Announces Reverse Stock Split
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEWTOWN, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-15 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time on May 1, 2025.
Read More
About Helius Medical Technologies, Inc. (HSDT)
- IPO Date 2014-06-27
- Website https://heliusmedical.com
- Industry Medical - Devices
- CEO Dane Carl Andreeff
- Employees 21